A network meta-analysis of 12 RCTs found GLP-1 receptor agonists reduce weight by 4.2 kg and BMI by 2.1 kg/m² in adolescents with overweight/obesity, with semaglutide producing the greatest weight loss.
-4.21 kg weight lossGLP-1 receptor agonists reduced weight by an average of 4.2 kg in adolescents with overweight or obesity, with semaglutide showing the greatest effect
What the researchers found
GLP-1RAs vs placebo: weight -4.21 kg (CI -7.08 to -1.35), BMI -2.11 kg/m² (CI -3.60 to -0.62). Network meta-analysis ranking: semaglutide > exenatide > liraglutide > lixisenatide for weight reduction. Longer therapy duration associated with greater reductions. Consistent effects in T2DM subgroup.
Why it matters
Adolescent obesity is a growing crisis with limited pharmacological options. This meta-analysis provides the first head-to-head comparison of GLP-1 drugs in youth, identifying semaglutide as the most effective option and establishing that these peptide medications work in younger populations.
The numbers in context
Searched 5 databases and registries through March 2024. Primary outcome: weight change. Pairwise and network meta-analyses performed.
How the study worked
Systematic review and network meta-analysis. Five databases searched through March 2024. 12 eligible RCTs with 883 participants. Pairwise meta-analysis (GLP-1RAs vs placebo) and drug-wise NMA. Primary outcome: weight change. Secondary: BMI, waist circumference, body fat, adverse events.
Who was studied
Adolescents with overweight or obesity with or without T2DM from RCTs
What this study cannot tell us
Only 12 trials with 883 participants — relatively limited evidence base. Uncertain evidence on body fat and serious adverse events. No long-term data beyond trial durations. Cost and access barriers not addressed. Network meta-analysis assumptions (transitivity, consistency) may not fully hold with heterogeneous populations.
How to read the evidence
Rated strong: systematic review with both pairwise and network meta-analyses of RCTs. Limited by small total sample (883 participants) and uncertain adverse event data.
When this study was published
Published in 2024. The first network meta-analysis comparing GLP-1 drugs head-to-head in adolescent populations.
The bigger picture
As childhood obesity rates continue to rise globally, having evidence-based pharmacological options becomes crucial. This meta-analysis positions GLP-1 peptide drugs — particularly semaglutide — as viable treatments for adolescent obesity, potentially preventing decades of obesity-related complications if used early.
Questions still open
- What are the long-term effects of GLP-1 drugs started during adolescence — do benefits persist into adulthood?
- Should semaglutide be the first-line GLP-1 drug for adolescent obesity based on this ranking?
- What is the optimal duration of GLP-1 therapy in adolescents — and what happens when treatment stops?
Common questions
Can teenagers take GLP-1 drugs for weight loss?
Which GLP-1 drug works best for adolescent weight loss?
Read the original research
Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.
Diabetes, obesity & metabolism, 26(10), 4302-4317
Citation
Shamim, Muhammad Aaqib; Patil, Amol N; Amin, Ulfat; Roy, Tuli; Tiwari, Krishna; Husain, Noor; Kumar, Jogender; Chenchula, Santenna; Rao, Priyanka; Ganesh, Venkata; Varthya, Shoban Babu; Singh, Surjit; Shukla, Ravindra; Rastogi, Ashu; Gandhi, Aravind P; Satapathy, Prakisini; Sah, Ranjit; Padhi, Bijaya Kumar; Dwivedi, Pradeep; Khunti, Kamlesh. (2024). Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.. Diabetes, obesity & metabolism, 26(10), 4302-4317. https://doi.org/10.1111/dom.15777